Accumulation of p27KIP1 is associated with BMP2-induced growth arrest and neuronal differentiation of human neuroblastoma-derived cell lines

Biochemical and Biophysical Research Communications

Volumn 307, Issue 1, 2003, Pages 206-213

  Nakamura, Yohko ^a,b   Ozaki, Toshinori ^a   Koseki, Haruhiko ^b   Nakagawara, Akira ^a   Sakiyama, Shigeru ^a  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

BMP2; DAN; Neuroblastoma; Neuronal differentiation; p27KIP1; p53; p73

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; PROTEIN DAN; PROTEIN DERIVATIVE; PROTEIN P21; PROTEIN P27; PROTEIN P53; S PHASE KINASE ASSOCIATED PROTEIN 2; SMAD PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO (ANATOMY); FROG; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION;

ANURA;

EID: 0038049378     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)01138-0     Document Type: Article

References (35)

1. Bolande R.P. The neurocristopathies: a unifying concept of disease arising in neural crest maldevelopment. Hum. Pathol. 5:1974;409-429.
2. Brodeur G.M., Nakagawara A. Molecular basis of clinical heterogeneity in neuroblastoma. Am. J. Pediatr. Hematol. Oncol. 14:1992;111-116.
3. Nakagawara A., Arima M., Azar C.G., Scavarda N.J., Brodeur G.M. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res. 52:1992;1364-1368.
4. Nakagawara A., Arima-Nakagawara M., Scavarda N.J., Azar C.G., Cantor A.B., Brodeur G.M. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N. Engl. J. Med. 328:1993;847-854.
5. Suzuki T., Bogenmann E., Shimada H., Stram D., Seeger R.C. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J. Natl. Cancer Inst. 85:1993;377-384.
6. Azar C.G., Scavarda N.J., Reynolds C.P., Brodeur G.M. Multiple defects of the nerve growth factor receptor in human neuroblastomas. Cell Growth Differ. 1:1990;421-428.
7. Nakagawara A., Brodeur G.M. Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study. Eur. J. Cancer. 33:1997;2050-2053.
8. Sidell N.J. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J. Natl. Cancer Inst. 68:1982;589-596.
9. Khan A.A., Villablanca J.G., Reynolds C.P., Avramis V.I. Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation. Cancer Chemother. Pharmacol. 39:1996;34-41.
10. Gaetano C., Matsumoto K., Thiele C.J. Retinoic acid negatively regulates p34cdc2 expression during human neuroblastoma differentiation. Cell Growth Differ. 2:1991;487-493.
11. Kip1: a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line. Oncogene. 16:1998;3337-3343.
12. Kip1 accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation. Oncogene. 19:2000;51-60.
13. De Laurenzi V., Raschella G., Barcaroli D., Annicchiarico-Petruzzelli M., Ranalli M., Catani M.V., Tanno B., Costanzo A., Levrero M., Melino G. Induction of neuronal differentiation by p73 in a neuroblastoma cell line. J. Biol. Chem. 275:2000;15226-15231.
14. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., Hewick R.M., Wang E.A. Novel regulators of bone formation: molecular clones and activities. Science. 242:1988;1528-1534.
15. Wozney J.M. The bone morphogenetic protein family and osteogenesis. Mol. Reprod. Dev. 32:1992;160-167.
16. Reddi A.H. Bone and cartilage differentiation. Curr. Opin. Genet. Dev. 4:1994;737-744.
17. Hsu D.R., Economides A.N., Wang X., Eimon P.M., Harland R.M. The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol. Cell. 1:1998;673-683.
18. Pearce J.J., Penny G., Rossant J. A mouse cerberus/Dan-related gene family. Dev. Biol. 209:1999;98-110.
19. Iwasaki S., Hattori A., Sato M., Tsujimoto M., Kohno M. Characterization of the bone morphogenetic protein-2 as a neurotrophic factor. Induction of neuronal differentiation of PC12 cells in the absence of mitogen-activated protein kinase activation. J. Biol. Chem. 271:1996;17360-17365.
20. Baumann M., Gires O., Kolch W., Mischak H., Zeidler R., Pich D., Hammerschmidt W. The PKC targeting protein RACK1 interacts with the Epstein-Barr virus activator protein BZLF1. Eur. J. Biochem. 267:2000;3891-3901.
21. Kretzschmar M., Liu F., Hata A., Doody J., Massague J. The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev. 11:1997;984-995.
22. Massague J., Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 19:2000;1745-1754.
23. Ishisaki A., Yamato K., Hashimoto S., Nakao A., Tamaki K., Nonaka K., Dijke P., Sugino H., Nishihara T. Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells. J. Biol. Chem. 274:1999;13637-13642.
24. Cervello M., D'Amelio L., Tesoro V., Rougon G., Matranga V. Expression of PSA-N-CAM in human neuroblastoma cells induced to neuronal differentiation by retinoic acid. Eur. J. Cell Biol. 73:1997;270-275.
25. Kawamura C., Kizaki M., Yamato K., Uchida H., Fukuchi Y., Hattori Y., Koseki T., Nishihara T., Ikeda Y. Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood. 96:2000;2005-2011.
26. Nakamura Y., Ozaki T., Ichimiya S., Nakagawara A., Sakiyama S. Ectopic expression of DAN enhances the retinoic acid-induced neuronal differentiation in human neuroblastoma cell lines. Biochem. Biophys. Res. Commun. 243:1998;722-726.
27. Shinbo J., Ozaki T., Nakagawa T., Watanabe K., Nakamura Y., Yamazaki M., Moriya H., Nakagawara A., Sakiyama S. p73-dependent expression of DAN during cisplatin-induced cell death and osteoblast differentiation. Biochem. Biophys. Res. Commun. 295:2002;501-507.
28. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X., Ferrara P., McKeon F., Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 90:1997;809-819.
29. DeGregori J., Kowalick T., Nevins J.R. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol. Cell. Biol. 15:1995;4215-4224.
30. Carrano A.C., Eytan E., Hershko A., Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell. Biol. 1:1999;193-199.
31. Kip1 degradation and induces S phase in quiescent cells. Nat. Cell Biol. 1:1999;207-214.
32. Tsvetkov L.M., Yeh K.H., Lee S.J., Sun H., Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr. Biol. 9:1999;661-664.
33. Masuda T.A., Inoue H., Sonoda H., Mine S., Yoshikawa Y., Nakayama K., Nakayama K., Mori M. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 62:2002;3819-3825.
34. Shah N.M., Groves A.K., Anderson D.J. Alternative neural crest cell fates are instructively promoted by TGFbeta superfamily members. Cell. 85:1996;331-343.
35. Gomez-Santos C., Ambrosio S., Ventura F., Ferrer I., Reiriz J. TGF-beta1 increases tyrosine hydroxylase expression by a mechanism blocked by BMP-2 in human neuroblastoma SH-SY5Y cells. Brain Res. 958:2002;152-160.